Skip to main content
SpringerLink
Log in

Clopidogrel with Aspirin Is the Optimal Antiplatelet Regimen for Intracoronary Stenting

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Malone AP. Salmon Smith Barney Equity Research: Medical supplies and technology, April 3, 1998, Company Analysis. Guidant Corporation.

  2. Serruys PW, Strauss BH, Beatt KJ, et al. Angiographic follow-up after placement of a self-expanding coronary artery stent. N Engl J Med 1991;324:13–17.

    Google Scholar 

  3. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496–501.

    Google Scholar 

  4. Serruys PW, DeJaegere P, Kiemeneij F, et al. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489–495.

    Google Scholar 

  5. Schomig A, Neumann F-J, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084–1089.

    Google Scholar 

  6. Mills DCB, Puri R, Hu C-J, et al. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb 1992;12:430–436.

    Google Scholar 

  7. Boneu B, Destelle G, on behalf of the study group. Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemost 1996;76:939–943.

    Google Scholar 

  8. Di Perri T, Pasini FL, Frigerio C, et al. Pharmacodynamics of ticlopidine in man in relation to plasma and blood cell concentration. Eur J Clin Pharmacol 1991;41:429–434.

    Google Scholar 

  9. Mak KH, Belli G, Ellis SG, Moliterno DJ. Subacute stent thrombosis: Evolving issues and current concepts. J Ame Coll Cardiol 1996;27:494–503.

    Google Scholar 

  10. Schulen H, Kastrati A, Dirschinger J, et al. Intracoronary stenting and risk for major adverse cardiac events during the first month. Circulation 1998;98:104–111.

    Google Scholar 

  11. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87–92.

    Google Scholar 

  12. Steinhubl SR, Balog C, Topol EJ. Pretreatment with ticlopidine prior to stenting is associated with a substantial decrease in complications. Data from the EPISTENT trial (abstr) Circulation 1998.

  13. Steinhubl SR, Lauer MS, Mukherjee DP, et al. The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions. J Am Coll Cardiol 1998, in press.

  14. Caplain H, Kieffer G, Thiercelin JF, Thebault JJ. Tolerance and clinical pharmacology of repeated administration of clopidogrel (SR 25990 C) a new antiplatelet agent, at three dose levels in normal healthy volunteers (abstr). Thromb Haemost 1989;62:410.

    Google Scholar 

  15. Bachman F, Savcic M, Hauert J, Geudelin B, Kieffer G, Cariou R. Rapid onset of inhibition of ADP-induced platelet aggregation by a loading dose of clopidogrel (abstr). Eur Heart J 1996;17:263.

    Google Scholar 

  16. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;1:1216–1220.

    Google Scholar 

  17. Hass WK, Easton JD, Adams HP, Jr. et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high risk patients. N Engl J Med 1989;321:501–507.

    Google Scholar 

  18. Wysowksi DK, Bacsanyi J. Blood dyscrasias and hematologic reactions in ticlopidine users. JAMA 1996;276:952.

    Google Scholar 

  19. Bennet CL, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PR, Kwaan HC, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med 1998;128:541–544.

    Google Scholar 

  20. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996;348:1329–1339.

    Google Scholar 

  21. Anonymous. Clopidogrel for reduction of atherosclerotic events. Medical Letter 1998;40:59–60.

  22. Serruys PW, van Hout B, Bonnier H, et al. Randomised trial of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet 1998;352:673–681.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Wilford Hall Medical Center, Lackland, AFB, Texas

    Steven R. Steinhubl

  2. Department of Cardiology and the Joseph J. Jacobs Center for Thrombosis and Vascular Biology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA

    Eric J. Topol

Authors
  1. Steven R. Steinhubl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric J. Topol
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Steinhubl, S.R., Topol, E.J. Clopidogrel with Aspirin Is the Optimal Antiplatelet Regimen for Intracoronary Stenting. J Thromb Thrombolysis 7, 227–231 (1999). https://doi.org/10.1023/A:1008981408216

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1008981408216

Keywords

Search

Navigation